CRIS catalyst calendar

CURIS INC

Upcoming catalysts
3
Cash runway
1.7 months
Cash & investments
$5M

CURIS INC is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Biological Products, (No Diagnostic Substances).

The next scheduled catalyst is Next quarterly earnings (projected) on November 10, 2026, a projected date rather than a confirmed one. There are 3 upcoming events on record.

Cash runway is approximately 1.7 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.

Across 10 concluded trials, 80% reached completion rather than being terminated or withdrawn.

Upcoming catalysts

DateEventTypePhase
November 10, 2026 est. Next quarterly earnings (projected) Earnings —
July 15, 2027 CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL) Trial Milestone Phase 1/Phase 2
November 15, 2027 A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies Trial Milestone Phase 2

Track CRIS alongside other companies. Add it to a watchlist and see every catalyst on one calendar.

Open CRIS in the tracker

Recent history

DateEventTypePhase
July 30, 2026 8-K filed: Listing / standard notice Corporate —
May 12, 2026 Quarterly results filed (8-K) Earnings —
May 1, 2026 8-K filed: Listing / standard notice Corporate —
March 19, 2026 Quarterly results filed (8-K) Earnings —
March 17, 2026 8-K filed: Leadership change Corporate —
February 9, 2026 8-K filed: Listing / standard notice Corporate —
January 8, 2026 8-K filed: Material agreement, Other event Corporate —
November 6, 2025 Quarterly results filed (8-K) Earnings —
October 24, 2025 8-K filed: Listing / standard notice Corporate —
August 22, 2025 8-K filed: Listing / standard notice Corporate —
August 8, 2025 8-K filed: Other event Filing —
August 5, 2025 Quarterly results filed (8-K) Earnings —
July 2, 2025 8-K filed: Material agreement, Reg FD disclosure, Other event Corporate —
May 22, 2025 8-K filed: Leadership change Corporate —
May 6, 2025 Quarterly results filed (8-K) Earnings —
May 19, 2023 Phase 1 Study of CI-8993 Anti-VISTA Antibody in Patients With Advanced Solid Tumor Malignancies Trial Milestone Phase 1
October 9, 2020 Study to Assess the Safety, Tolerability and Pharmacokinetics of Fimepinostat (CUDC-907) in Patients With Lymphoma Trial Milestone Phase 1
May 7, 2020 A Study of CA-170 (Oral PD-L1, PD-L2 and VISTA Checkpoint Antagonist) in Patients With Advanced Tumors and Lymphomas Trial Milestone Phase 1
May 31, 2019 Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Subjects With Advanced/Relapsed Solid Tumors Trial Milestone Phase 1
May 28, 2019 Study to Evaluate the Efficacy and Safety of CUDC-907 in Patients With RR DLBCL, Including Patients With MYC Alterations Trial Milestone Phase 2

About this data

Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.

Last updated 2026-10-14.